These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 39372417)
21. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary. ; ; Diabetologia; 2024 Jun; ():. PubMed ID: 38869512 [TBL] [Abstract][Full Text] [Related]
22. Role of the type 3 cytokines IL-17 and IL-22 in modulating metabolic dysfunction-associated steatotic liver disease. Abdelnabi MN; Hassan GS; Shoukry NH Front Immunol; 2024; 15():1437046. PubMed ID: 39156888 [TBL] [Abstract][Full Text] [Related]
23. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). ; ; ; J Hepatol; 2024 Sep; 81(3):492-542. PubMed ID: 38851997 [TBL] [Abstract][Full Text] [Related]
25. Egr2 drives the differentiation of Ly6C Iwata A; Maruyama J; Natsuki S; Nishiyama A; Tamura T; Tanaka M; Shichino S; Seki T; Komai T; Okamura T; Fujio K; Tanaka M; Asano K Commun Biol; 2024 Jun; 7(1):681. PubMed ID: 38831027 [TBL] [Abstract][Full Text] [Related]
26. Active role of the immune system in metabolic dysfunction-associated steatotic liver disease. Mori T; Yoshio S; Kakazu E; Kanto T Gastroenterol Rep (Oxf); 2024; 12():goae089. PubMed ID: 39411101 [TBL] [Abstract][Full Text] [Related]
27. Implications of Microbiota and Immune System in Development and Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease. Popov J; Despot T; Avelar Rodriguez D; Khan I; Mech E; Khan M; Bojadzija M; Pai N Nutrients; 2024 May; 16(11):. PubMed ID: 38892602 [TBL] [Abstract][Full Text] [Related]
28. Therapeutic management of metabolic dysfunction associated steatotic liver disease. Zeng J; Fan JG; Francque SM United European Gastroenterol J; 2024 Mar; 12(2):177-186. PubMed ID: 38193865 [TBL] [Abstract][Full Text] [Related]
29. Small intestinal bacterial overgrowth in obese patients with biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: a cross-sectional study. Ortiz-López N; Madrid AM; Aleman L; Zazueta A; Smok G; Valenzuela-Pérez L; Poniachik J; Beltrán CJ Front Med (Lausanne); 2024; 11():1376148. PubMed ID: 38854668 [TBL] [Abstract][Full Text] [Related]
30. Incretin-based investigational therapies for the treatment of MASLD/MASH. Brouwers B; Rao G; Tang Y; Rodríguez Á; Glass LC; Hartman ML Diabetes Res Clin Pract; 2024 May; 211():111675. PubMed ID: 38636848 [TBL] [Abstract][Full Text] [Related]
31. Intricate interplay between cell metabolism and necroptosis regulation in metabolic dysfunction-associated steatotic liver disease: A narrative review. Afonso MB; David JC; Alves MI; Santos AA; Campino G; Ratziu V; Gautheron J; Rodrigues CMP Metabolism; 2024 Sep; 158():155975. PubMed ID: 39004396 [TBL] [Abstract][Full Text] [Related]